Search Results - "PATHIL, Anita"

Refine Results
  1. 1

    Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study1 by Krawczyk, Marcin, Rau, Monika, Schattenberg, Jörn M., Bantel, Heike, Pathil, Anita, Demir, Münevver, Kluwe, Johannes, Boettler, Tobias, Lammert, Frank, Geier, Andreas

    Published in Journal of lipid research (01-01-2017)
    “…The PNPLA3 p.I148M, TM6SF2 p.E167K, and MBOAT7 rs641738 variants represent genetic risk factors for nonalcoholic fatty liver disease (NAFLD). Here we…”
    Get full text
    Journal Article
  2. 2

    Circulating Phospholipid Patterns in NAFLD Patients Associated with a Combination of Metabolic Risk Factors by Tiwari-Heckler, Shilpa, Gan-Schreier, Hongying, Stremmel, Wolfgang, Chamulitrat, Walee, Pathil, Anita

    Published in Nutrients (21-05-2018)
    “…Non-alcoholic fatty liver disease (NAFLD) is associated with inefficient macro- and micronutrient metabolism, and alteration of circulating phospholipid…”
    Get full text
    Journal Article
  3. 3
  4. 4
  5. 5
  6. 6

    Anti-inflammatory properties of ursodeoxycholyl lysophosphatidylethanolamide in endotoxin-mediated inflammatory liver injury by Ludwig, Johannes Maximilian, Zhang, Yuling, Chamulitrat, Walee, Stremmel, Wolfgang, Pathil, Anita

    Published in PloS one (24-05-2018)
    “…Endotoxin-mediated liver inflammation is a key component of many acute and chronic liver diseases contributing to liver damage, fibrosis and eventually organ…”
    Get full text
    Journal Article
  7. 7
  8. 8

    Bivalent Ligand UDCA-LPE Inhibits Pro-Fibrogenic Integrin Signalling by Inducing Lipid Raft-Mediated Internalization by Su, Jie, Gan-Schreier, Hongying, Goeppert, Benjamin, Chamulitrat, Walee, Stremmel, Wolfgang, Pathil, Anita

    “…Ursodeoxycholyl lysophosphatidylethanolamide (UDCA-LPE) is a synthetic bile acid-phospholipid conjugate with profound hepatoprotective and anti-fibrogenic…”
    Get full text
    Journal Article
  9. 9

    Could inherited predisposition drive non-obese fatty liver disease? Results from German tertiary referral centers by Krawczyk, Marcin, Bantel, Heike, Rau, Monika, Schattenberg, Jörn M, Grünhage, Frank, Pathil, Anita, Demir, Münevver, Kluwe, Johannes, Boettler, Tobias, Weber, Susanne N, Geier, Andreas, Lammert, Frank

    Published in Journal of human genetics (01-05-2018)
    “…Non-alcoholic fatty liver disease (NAFLD) is frequent among obese individuals with metabolic syndrome. Variants PNPLA3 p.I148M, TM6SF2 p.E167K and MBOAT7…”
    Get full text
    Journal Article
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14

    Hepatic sarcoidosis: Clinical characteristics and outcome by Graf, Christiana, Arncken, Jeannette, Lange, Christian M., Willuweit, Katharina, Schattenberg, Jörn M., Seessle, Jessica, Lang-Meli, Julia, Böttler, Tobias, Dietz, Julia, Wetzstein, Nils, Mondorf, Antonia, Vermehren, Johannes, Rohde, Gernot, Zeuzem, Stefan, Pathil, Anita

    Published in JHEP reports (01-12-2021)
    “…Clinical manifestation of hepatic involvement in sarcoidosis can vary from asymptomatic disease to severe complications such as cirrhosis and portal…”
    Get full text
    Journal Article
  15. 15

    Loss of aquaporin-4 expression and putative function in non-small cell lung cancer by Warth, Arne, Muley, Thomas, Meister, Michael, Herpel, Esther, Pathil, Anita, Hoffmann, Hans, Schnabel, Philipp A, Bender, Christian, Buness, Andreas, Schirmacher, Peter, Kuner, Ruprecht

    Published in BMC cancer (06-05-2011)
    “…Aquaporins (AQPs) have been recognized to promote tumor progression, invasion, and metastasis and are therefore recognized as promising targets for novel…”
    Get full text
    Journal Article
  16. 16

    Epigenetic combination therapy as a tumor‐selective treatment approach for hepatocellular carcinoma by Venturelli, Sascha, Armeanu, Sorin, Pathil, Anita, Hsieh, Chih‐Jen, Weiss, Thomas S., Vonthein, Reinhard, Wehrmann, Manfred, Gregor, Michael, Lauer, Ulrich M., Bitzer, Michael

    Published in Cancer (15-05-2007)
    “…BACKGROUND. Innovative epigenetic therapeutics comprise histone deacetylase inhibitors (HDAC‐I) and demethylating agents (DA). It was recently found that…”
    Get full text
    Journal Article
  17. 17
  18. 18
  19. 19
  20. 20

    DMBT1 expression in biliary carcinogenesis with correlation of clinicopathological data by Goeppert, Benjamin, Roessler, Stephanie, Becker, Natalia, Zucknick, Manuela, Vogel, Monika N, Warth, Arne, Pathil‐Warth, Anita, Mehrabi, Arianeb, Schirmacher, Peter, Mollenhauer, Jan, Renner, Marcus

    Published in Histopathology (01-06-2017)
    “…Aims Deleted in malignant brain tumours 1 (DMBT1) exerts functions in the regulation of epithelial differentiation and inflammation and has been proposed as a…”
    Get full text
    Journal Article